Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

124 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial.
Velikova G, Morden JP, Haviland JS, Emery C, Barrett-Lee P, Earl H, Bloomfield D, Brunt AM, Canney P, Coleman R, Verrill M, Wardley A, Bertelli G, Ellis P, Stein R, Bliss JM, Cameron D; TACT2 Trial Management Group. Velikova G, et al. Among authors: wardley a. Lancet Oncol. 2023 Dec;24(12):1359-1374. doi: 10.1016/S1470-2045(23)00460-6. Epub 2023 Nov 2. Lancet Oncol. 2023. PMID: 37926100 Free article. Clinical Trial.
Pathway level alterations rather than mutations in single genes predict response to HER2-targeted therapies in the neo-ALTTO trial.
Shi W, Jiang T, Nuciforo P, Hatzis C, Holmes E, Harbeck N, Sotiriou C, Peña L, Loi S, Rosa DD, Chia S, Wardley A, Ueno T, Rossari J, Eidtmann H, Armour A, Piccart-Gebhart M, Rimm DL, Baselga J, Pusztai L. Shi W, et al. Among authors: wardley a. Ann Oncol. 2018 Oct 1;29(10):2152. doi: 10.1093/annonc/mdx805. Ann Oncol. 2018. PMID: 29701764 Free PMC article. No abstract available.
Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2).
Chua S, Smith IE, A'Hern RP, Coombes GA, Hickish TF, Robinson AC, Laing RW, O'Brien ME, Ebbs SR, Hong A, Wardley A, Mughal T, Verrill M, Dubois D, Bliss JM; TOPIC Trial Group. Chua S, et al. Among authors: a hern rp, wardley a. Ann Oncol. 2005 Sep;16(9):1435-41. doi: 10.1093/annonc/mdi276. Epub 2005 Jun 9. Ann Oncol. 2005. PMID: 15946977 Free article. Clinical Trial.
TEXAS (Taxotere EXperience with Anthracyclines Study) trial: mature results of activity/toxicity of docetaxel given with anthracyclines in a community setting, as first line therapy for MBC.
Malinovszky K, Johnston S, Barrett-Lee P, Howell A, Verrill M, O'Reilly S, Houston S, Wardley A, Grieve R, Leonard R. Malinovszky K, et al. Among authors: wardley a. Cancer Chemother Pharmacol. 2007 Feb;59(3):413-8. doi: 10.1007/s00280-006-0303-9. Epub 2006 Sep 29. Cancer Chemother Pharmacol. 2007. PMID: 17009036 Clinical Trial.
tAnGo: a randomised phase III trial of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy for early breast cancer: a prospective pulmonary, cardiac and hepatic function evaluation.
Wardley AM, Hiller L, Howard HC, Dunn JA, Bowman A, Coleman RE, Fernando IN, Ritchie DM, Earl HM, Poole CJ; tAnGo Trial Collaborators. Wardley AM, et al. Br J Cancer. 2008 Aug 19;99(4):597-603. doi: 10.1038/sj.bjc.6604538. Epub 2008 Jul 29. Br J Cancer. 2008. PMID: 18665163 Free PMC article. Clinical Trial.
124 results